Article Text

PDF
Letters
Photodynamic therapy may worsen the prognosis of highly myopic choroidal neovascularisation treated by intravitreal bevacizumab
  1. J M Ruiz-Moreno1,2,
  2. J A Montero2,3,
  3. F Gomez-Ulla4,5
  1. 1
    Department of Ophthalmology, Castilla La Mancha University, Albacete, Spain
  2. 2
    Alicante Institute of Ophthalmology, VISSUM, Vitreo-Retinal Unit, Alicante, Spain
  3. 3
    Pio del Rio Hortega University Hospital, Valladolid, Spain
  4. 4
    Technological Institute of Ophthalmology, Santiago de Compostela, Spain
  5. 5
    Complejo Hospitalario Universitario, Santiago de Compostela, Spain
  1. Correspondence to Dr J M Ruiz-Moreno, Departamento de Ciencias Médicas, Facultad de Medicina, Avda de Almansa, 14, 02006 Albacete, Spain; josemaria.ruiz{at}uclm.es

Statistics from Altmetric.com

Myopic maculopathy is the main cause of vision loss among highly myopic patients, and the leading aetiology of subfoveal choroidal neovascularisation (CNV) among patients <50 years old. Different therapeutic approaches have been used to treat myopic CNV, including argon laser photocoagulation, surgery and photodynamic therapy (PDT). New anti-angiogenic drugs have been used to treat subfoveal CNV secondary to high myopia.1 2

The purpose of this study is to report the influence of previous PDT on the visual outcome of subfoveal and juxtafoveal CNV in highly myopic patients treated by intravitreal bevacizumab (IB).

Twenty-nine eyes from 28 highly myopic patients with subfoveal and juxtafoveal CNV were treated by three-monthly intravitreal injections of 1.25 mg bevacizumab. Patients on treatment by PDT were started on IB if they were losing visual acuity or CNV did not respond to PDT.

Best …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.